Fracture risk remains reduced one year after discontinuation of risedronate

Osteoporosis International

Volumn 19, Issue 3, 2008, Pages 365-372

  Watts, N B ^a   Chines, A ^b   Olszynski, W P ^c   McKeever, C D ^d   McClung, M R ^e   Zhou, X ^b   Grauer, A ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c Midtown Medical Centre   (Canada)

^d McKeever Orthopedic Clinic   (United States)

^e OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Bone mineral density; Bone turnover; Osteoporotic fracture; Postmenopausal osteoporosis; Risedronate; Vertebral fractures

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL PROTOCOL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FEMUR TROCHANTERIC FRACTURE; HIP FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORBIDITY; MORPHOMETRICS; PRIORITY JOURNAL; RADIUS FRACTURE; RISK ASSESSMENT; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; SPINAL FRACTURES;

EID: 38849130073     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0460-7     Document Type: Article

References (29)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
2. Felsenberg D, Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27:1-11
3. Lindsay R, Boonen S, Burgio D et al (2004) Significant reduction of bone resorption with risedronate treatment in as soon as one week. J Bone Miner Res 19(Suppl. 1):SU434
4. Borah B, Ritman EL, Dufresne TE et al (2005) The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 37:1-9
5. Dufresne TE, Chmielewski PA, Manhart MD et al (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423-432
6. Watts NB, Cooper C, Lindsay R et al (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261
7. Watts NB, Geusens P, Barton I et al (2005) The relationship between changes in bone mineral density and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in bone mineral density. J Bone Miner Res 20:2097-2104
8. Eastell R, Barton I, Hannon RA et al (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
9. Chapurlat RD, Palermo L, Ramsay P et al (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16:842-848
10. Watts NB, Magowan S, Brown JP et al (2005) Risedronate demonstrates efficacy to reduce fragility fractures independent of treatment-related BMD changes. J Bone Miner Res 20(Suppl. 1):SA407
11. Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258
12. Roux C, Seeman E, Eastell R et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433-439
13. Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tiss Int 74:129-135
14. Sorensen OH, Crawford GM, Mulder H et al (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120-126
15. Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
16. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
17. Borah B, Dufresne TE, Chmielewski PA et al (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736-746
18. Sarkar S, Reginster JY, Crans GG et al (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401
19. Cummings SR, Karpf DB, Harris F et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289
20. Mellstrom DD, Sorensen OH, Goemaere S et al (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462-468
21. Bone HG, Hosking D, Devogelaer J-P et al (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
22. Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259-1269
23. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
24. Ruggiero SL, Mehrotra B, Rosenberg TJ et al (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
25. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761
26. Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
27. Greenspan SL, Emkey RD, Bone HG et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875-883
28. Stock JL, Bell NH, Chesnut CH et al (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297
29. Colon-Emeric CS (2006) Ten vs. five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA 296:2968-2969